PPSS Group Launch Next Generation Body Armour Offering Previously Unthinkable Levels Of Protection
4.12.2019 16:30:00 EET | Business Wire | Press release
PPSS Group's next generation of high-performance body armour is taking personal protection to a completely new-found level.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191204005491/en/
PPSS Group using carbon fibre composites technology for their latest development (Photo: Business Wire)
Thoroughly field tested, the body armour will be made available from Monday 06 January 2020. A demonstration of the body armour is available to view here.
Made from Auxilam™, a unique carbon fibre composite material, this latest body armour will protect the wearer from even the most vicious and brutal types of edged weapon and shanks imaginable.
Utilising a combination of the incredible strength of carbon fibre, the auxetic properties of Auxilam™ technology and some additional ‘top secret’ assets derived from the specially developed composite structure, this next generation of body armour offers a truly outstanding balance of weight, protection, performance and durability.
Comparing it with PPSS Group’s highly acclaimed polycarbonate-based stab resistant vests, the company is claiming a reduction of 19% in thickness (utilising a 3.9mm carbon fibre composite) and a 6.6% lower aerial density and reduced weight for its latest development.
Yet, it will be certified to KR2/SP2 according to the UK Home Office Body Armour Standard, as well as NIJ Level 2 (Stab & Spike) and VPAM K2/D2 meaning it will offer a truly significant higher level of knife, spike and needle protection.
Government agencies and security companies will be able to chose from an array of different styles, ranging from covert, overt to hi viz overt options.
Robert Kaiser, CEO of PPSS Group states: “Law Enforcement, Border Force, Immigration, Customs and Prison Officers are being attacked by criminals carrying and using knives, machetes, shanks, blunt objects and hypodermic needles every day.”
“Our key objective is to protect those men and women even more effectively. Using the very latest in technology and following extensive research and development, our latest body armour is now offering previously absolutely unthinkable levels of protection.”
“It also offers exceptional, VPAM certified protection from blunt objects, effectively reducing the risks of blunt force trauma injuries e.g. internal bleeding.”
The UK headquartered firm has been supplying countless of homeland security agencies in countries around the world with their widely respected polycarbonate-based stab resistant vests over the past ten years.
Please contact PPSS Group directly in case you have any questions in regards to this press release.
About PPSS Group:
PPSS Group is specialised in the development, manufacturing and supply of high-performance personal protective equipment, offering unrivalled protection from edged weapons, blunt force trauma and even human bites. PPSS Group’s social media presence: Facebook, LinkedIn, Twitter, and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191204005491/en/
Contact information
Media Contact:
Ryan Vickers – Chief Development Officer (CDO)
E: info@ppss-group.com
T: +44 (0) 845 5193953
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OdysseyRe Announces New Co-Chief Underwriting Officers for EMEA18.5.2026 10:00:00 EEST | Press release
Odyssey Reinsurance Company (OdysseyRe) today announced the appointments of Tegwen Gromellon and Anne-Claire Serres as co-chief underwriting officers of its EMEA division, effective July 1. They succeed longtime Chief Underwriting Officer, Gaël Le Païh, who is retiring later this year following 36 years with the Company. Based in Paris, Serres joined OdysseyRe in 2018 as the market director for France and will lead the division’s business across France, Africa and the Middle East. Gromellon, who joined OdysseyRe in 2004, has served as market director for Germany, Austria, Benelux and Switzerland since 2019. He will take the lead for the rest of Europe, including the relationship with the Company’s representative office in Stockholm for the Nordic markets and across Turkey. “We are delighted to appoint both Tegwen and Anne-Claire to these important leadership positions,” said Isabelle Dubots-Lafitte, chief executive officer of EMEA for OdysseyRe. “These appointments recognize their sign
Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy18.5.2026 10:00:00 EEST | Press release
Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapies for the treatment of solid tumours, today announced safety and antitumour efficacy results from an interim review of the ongoing Phase 1/1b PARADIGM-1 trial of ZH9 in non-muscle invasive bladder cancer (NMIBC) patients. These data were shared via an oral podium presentation at the American Urology Association (AUA26) Annual Meeting. Prokarium CMO, Dr Josefin-Beate Holz said “These data demonstrate ZH9 as a universally applicable treatment for patients. As the treatment is very well tolerated and is showing impactful outcomes for early and BCG-non-responsive patients alike, it opens up the potential for ZH9 to be a transformative bladder saving treatment.” "There is a clear and urgent need to move beyond BCG. The current treatment burden—requiring up to 18 catheterisations in the first year— detrimentally impacts real-world compliance and patient outcomes," said Ibs Mahmood, CEO of Prokarium. "Pat
Arboris Capital Selects ROYC to Expand Private Markets Capabilities on CapGain Platform18.5.2026 10:00:00 EEST | Press release
Arboris Capital Limited (“Arboris”), a DIFC-based firm arranging alternative investments, authorised by the Dubai Financial Services Authority (DFSA), today announced that it has selected ROYC AB (“ROYC”), a private markets technology and infrastructure provider, to support the continued development of its private markets offering through its platform, CapGain. In its ongoing efforts to expand its private markets capabilities across the Middle East, Arboris has undertaken a strategic review of how to further scale its offering while maintaining the integrity of its existing platform. As a result, Arboris has chosen to integrate ROYC’s fund access, sourcing, and structuring capabilities into CapGain, complementing its existing infrastructure. CapGain is Arboris’s proprietary investment platform, purpose-built to facilitate access between international private market opportunities and Professional Investors in the region. CapGain provides fully digital investor onboarding and KYC, a secu
LogicMonitor and Deutsche Telekom Expand Partnership Across Europe18.5.2026 10:00:00 EEST | Press release
LogicMonitor®, the AI-first platform for Autonomous IT, today announced the expanded availability of its platform within Deutsche Telekom’s managed services portfolio across selected European markets, including DACH, Benelux, and the Nordics. The expansion builds on operational use of LogicMonitor in the United Kingdom since 2023, where it has supported Deutsche Telekom’s service teams in improving visibility across network, cloud, and hybrid infrastructure environments. Experience gained from these deployments is now informing broader service enablement across additional European markets. As enterprise IT environments grow more complex, organisations require more than visibility—they need predictive resilience. Through defined use cases, LogicMonitor complements Deutsche Telekom’s existing service management, monitoring, and security tooling, helping teams anticipate, detect, and resolve issues before they impact business operations. In the United Kingdom, the partnership has delivere
VahatiCor Appoints Harry D. Rowland, Ph.D., as Chief Executive Officer18.5.2026 09:00:00 EEST | Press release
VahatiCor, Inc., a medtech company developing interventional therapies for Coronary Microvascular Dysfunction (CMD), announced today the appointment of Harry D. Rowland, Ph.D., as Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260517830314/en/ VahatiCor CEO, Harry D. Rowland, Ph.D. Rowland previously served as Chief Executive Officer and President of Endotronix, where he led the development and commercialization of the Cordella™ Pulmonary Artery Sensor and Heart Failure System. Under his leadership, Endotronix raised over $150 million and grew to more than 150 employees. He also oversaw the PROACTIVE-HF pivotal trial from execution through FDA premarket approval and commercial launch. Following its acquisition by Edwards Lifesciences in 2024, Rowland stayed on to support key CMS national coverage and CE Mark milestones. "Harry has led a medical company through this arc before. He took Endotronix from
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom